Iceland· IS-880030

Maxitrol

A dexamethason mit antiinfektiva product containing dexamethasonum inn fosfat,neomycinum inn súlfat,polymyxinum b inn súlfat, registered in Iceland by Novartis Healthcare A/S. The same ATC class is registered in 11 of our 19 countries.

ATC S01CA01

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedMaxitrolATCS01CA01REGISTER NO.IS-880030PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Dexamethason mit antiinfektiva is registered in 11 of 19 countries.

Countries holding a registration under ATC S01CA01 (dexamethason mit antiinfektiva), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 7 of them publish a price we can compare per daily dose

Dexamethason mit antiinfektiva · ATC S01CA01

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Dexamethasonum INN fosfat,Neomycinum INN súlfat,Polymyxinum B INN súlfat
Manufacturer
Novartis Healthcare A/S
Country
Iceland (IS)
ATC code
S01CA01
ATC class
Dexamethason mit Antiinfektiva
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 1

1 priced
  • ean
    486886
    5 ml x1 glas
    ISK 2191

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e7b458d9-9284-44b2-9b6d-f7b3b81e5f5f
GET /v1/drugs/e7b458d9-9284-44b2-9b6d-f7b3b81e5f5f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Augndropar, dreifa",
  "source": "lyfjastofnun",
  "atc_raw": "S01CA01",
  "marketed": true,
  "strength": "1 mg/ml + 3.500 a.e./ml + 6000 a.e./ ml",
  "ma_number": "880030",
  "substance": "Dexamethasonum INN fosfat,Neomycinum INN súlfat,Polymyxinum B INN súlfat",
  "other_info": null,
  "legal_status": "(R) Lyfseðilsskylt",
  "ma_issued_serial": "33055"
}

See everything about dexamethason mit antiinfektiva.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.